MAPKBP1 and acute myeloid leukemia: We found that the CLIC4high group contained fewer NPM1 mutations (P = 0.0209) and more FLT3-ITD patients (P < 0.0001) and remarkably high expressions of BAALC (P = 0.0153), MAPKBP1 (P = 0.0153), RUNX1 (P = 0.0026), and TCF4 (P < 0.0001), which were proven to contribute to unfavorable outcomes in CN-AML.